drugset / Trial / NCT01217931
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
RandomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to compare 6 different 2-drug "sequences" of everolimus, bevacizumab, or pazopanib to learn how they may affect metastatic kidney cancer. For the 2-drug sequence, participants will receive 1 of these drugs and may start taking another of these drugs after that. Researchers will also study the safety of these 2-drug sequences.
Timeline
- Start
- 2011-01-19
- Primary completion
- 2028-01-31
- Completion
- 2028-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Subject | Pazopanib | Small molecule | 800 mg | Oral |